buthionine sulfoximine has been researched along with HIV Coinfection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, HY; Wu, MR; Zhang, HS; Zhou, HS; Zhou, Y | 1 |
| Dröge, W; Gmünder, H | 1 |
2 other study(ies) available for buthionine sulfoximine and HIV Coinfection
| Article | Year |
|---|---|
Nrf2 is involved in inhibiting Tat-induced HIV-1 long terminal repeat transactivation.
Topics: Acetylcysteine; Active Transport, Cell Nucleus; Buthionine Sulfoximine; Cell Nucleus; Enzyme Inhibitors; Gene Expression Regulation, Viral; Glutathione; HeLa Cells; HIV Infections; HIV-1; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; NF-E2-Related Factor 2; Reactive Oxygen Species; RNA, Small Interfering; tat Gene Products, Human Immunodeficiency Virus; Terminal Repeat Sequences; Transcriptional Activation; Virus Replication | 2009 |
Differential effects of glutathione depletion on T cell subsets.
Topics: Animals; Buthionine Sulfoximine; CD4-CD8 Ratio; Clone Cells; DNA; Glutathione; HIV Infections; Methionine Sulfoximine; Mice; Mice, Inbred C3H; Receptors, Interleukin-2; T-Lymphocyte Subsets | 1991 |